Skip to main content

Eligard (leuprorelin acetate) | For UK Healthcare Professionals

This promotional website has been developed and funded by Recordati Pharmaceuticals Ltd and is only intended for healthcare professionals based in the UK.
Prescribing Information (PI) and Adverse Event (AE) Reporting Information can be accessed via the link found at the bottom of this page.
Menu

RELY ON ELIGARD’S CONTROL

ELIGARD Atrigel™

depot formulation

minimises breakthroughs associated with the risk of potential progression*1,2

ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.1

Atrigel™ Technology: Sustained testosterone
suppression at the molecular level:

controlled-release-symbol

CONTROLLED AND SUSTAINED RELEASE2

Read More
breakthrough-symbol

LESS THAN 1% BREAKTHROUGHS2

Read More
treatment-adherance-symbol

GREATER LIKELIHOOD OF TREATMENT ADHERENCE VS ORAL THERAPIES2

Read More
*The EAU-recommended testosterone level is <20 ng/dL.3 This definition is important as better results are repeatedly observed with lower testosterone levels compared to 50 ng/dL.3,4

ELIGARD offers controlled and sustained release
of leuprorelin acetate between injections2

Asset 16@2x
Not all ADT formulations are the same: different administration technologies can significantly alter pharmacokinetics and effectiveness5
Asset 17@2x
ELIGARD Atrigel™ technology consists of a soluble polymer that ensures a sustained and stable release of leuprorelin2

Mixture of solvent and leuprorelin molecules2,4

Subcutaneous injection
The polymer solidifies on
contact with water molecules
in the dermis and forms a
solid in-situ depot
Asset-3b@2x

Continuous and extended release of leuprorelin

ELIGARD AtrigelTM provides reliability
for you and your patients:

delayed-onset-symbol

Testosterone levels maintained below 20ng/dL are associated with delayed onset of CRPC2,4,6-8

By maintaining testosterone levels associated with improved patient outcomes*

14-days-symbol

Testosterone suppression that extends beyond the dosing period†9

Supporting flexibility in injection scheduling10
subcutaneous-symbol

Subcutaneous injections lasting 3 and 6 months2

Consistent, sustained effectiveness – with the flexibility to choose the appropriate dosing interval for your patient2,11

*The EAU-recommended testosterone level is <20 ng/dL.3 This definition is important as better results are repeatedly observed with lower testosterone levels compared to 50 ng/dL.4

†Based on a pharmacokinetic/pharmacodynamic study with 1-monthly dosing in 32 healthy men.9

ADT, androgen deprivation therapy; EAU, European Association of Urology; CRPC, castrate-resistant prostate cancer.

Long-term control with no breakthroughs in over 99% of patients2

Testosterone breakthroughs have been associated with an increased risk of disease progression2

Once achieved, castration levels were maintained throughout the treatment with ELIGARD (testosterone breakthroughs in <1% of patients)2

Adapted from Tombal B, 2007.2

The 1-month formulation of Eligard is not marketed in the United Kingdom.

ELIGARD provides testosterone

suppression to <20 ng/dL with
<1% of breakthroughs1,2,12–14

Consider the importance of treatment adherence
for your prostate cancer patients:

25-51%

mean
non-adherence
rates

Mean non-adherence rates of 25‑51% were reported among prostate cancer patients receiving oral therapies15

Literature review of 4 studies reporting real‑world adherence to prostate cancer medications.15

More than

40%

of men
over 65

More than 40% of men
over 65 had poor or
very poor adherence to
prescribed oral ADT16

Clinical cohort of incident prostate cancer linked to the Swedish Prescribed Drug Register. 1406 men with a planned first line monotherapy anti-androgen treatment were identified. Factors potentially influencing adherence were explored using the medical possession ratio based on the individual prescribed daily dose.16

Injections may offer a distinct advantage
over oral medications in patients where
adherence is a potential concern17

ADT, androgen deprivation therapy.

Find out how can
support you and your patients       

VIEW ELIGARD PRESCRIBING INFORMATION

References

  1. ELIGARD Summary of Product Characteristics.
  2. Tombal B, et al. Eur Urol Suppl 2007;6:754–760.
  3. Cornford P, et al. EAU Guidelines. Edn. presented at EAU Paris April 2024. ISBN 978-94-92671-23-3.
  4. Shore ND, et al. BJU lnt. 2017;119(2):239–244.
  5. Crawford ED, et al. J Urol. 2021;205:554–560.
  6. Saltzstein D, et al. Ther Adv Urol. 2018;10(2):43–50.
  7. Pieczonka CM, et al. Rev Urol. 2018;20(2):63–68.
  8. Klotz L, et al. J Clin Oncol. 2015;33:1151-1156.
  9. Perez-Marrero R & Tyler RC. Expert Opin Pharmacother. 2004;5(2):447–457.
  10. Saltzstein D, et al. Ther Adv Urol. 2018;10(2):43–50.
  11. Sartor O. Eur Urol Suppl. 2006;5:905–910.
  12. Perez-Marrero R, et al. Clin Ther. 2002;24:1902–1914.
  13. Chu FM, et al. J Urol. 2002;168:1199–1203.
  14. Crawford ED, et al. J Urol. 2006;175:533–536.
  15. Higano CS, et al. J Urol. 2023;209(3):485–493.
  16. Grundmark B, et al. Eur J Clin Pharmacol. 2012;68(12):1619–1630.
  17. Fleshner NE, et al. Ther Adv Med Oncol. 2023;15:17588359231152845.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Recordati Pharmaceuticals Ltd on Local‑Safety@recordati.com

Contact us

Cookie Policy | Privacy Policy | Terms and Conditions

Information on the processing of personal data for Medical Information, 
Safety Reporting and Product Quality Complaint – click here

UK-ELIGA-0053 | September 2026 © 2026 Recordati